close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nkarta, Inc. - Common Stock (NQ:NKTX)

2.080 -0.010 (-0.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nkarta, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Positive Clinical Results Put Nkarta Stock on the Fast Track
NKTX stock is a fast mover, and a recent share-price bump came in the wake of exciting data from a "killer cell" anti-cancer research program. 
Via InvestorPlace
Executives Buy More Than $32M Of 3 Stocks
Although US stocks closed sharply lower on Friday, there were a few notable insider trades. 
Via Benzinga
How Is The Market Feeling About Nkarta Inc. - Common Stock?
Nkarta Inc. - Common Stock's (NASDAQ:NKTX) short percent of float has risen 8.05% since its last report. The company recently reported that it has 1.84 million shares sold short,... 
Via Benzinga
34 Stocks Moving In Tuesday's Mid-Day Session
Gainers Avadel Pharmaceuticals plc. (NASDAQ: AVDL) shares gained 36.3% to $5.74. Shares closed down 36% on Monday, seemingly on no news. Avadel issued a press release Tuesday... 
Via Benzinga
Expert Ratings for Nkarta
Analysts have provided the following ratings for Nkarta (NASDAQ:NKTX) within the last quarter: 
Via Benzinga
Investors Cheer Nkarta's First NK Cell Data With Multiple Complete Responses
 
Via Benzinga
71 Biggest Movers From Yesterday
Gainers Evoke Pharma, Inc. (NASDAQ: EVOK) shares jumped 118.5% to close at $0.86 on Tuesday. The FDA granted new drug product exclusivity to Evoke Pharma's Gimoti (... 
Via Benzinga
Futures Slide Ahead Of Tech Earnings Deluge
Markets in general are preoccupied by the prospect of tighter monetary policy conditions from global central banks to stem rising prices. 
Via Talk Markets
The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
10 Biggest Price Target Changes For Tuesday
HC Wainwright & Co. raised Nkarta, Inc. (NASDAQ: NKTX) price target from $25 to $36. Nkarta shares fell 7.2% to $17.38 in pre-market trading. 
Via Benzinga
Mid-Afternoon Market Update: Nasdaq Rises 70 Points; Eliem Therapeutics Shares Slide
U.S. stocks pared losses toward the end of trading, with the Nasdaq Composite gaining around 70 points on Monday. 
Via Benzinga
60 Biggest Movers From Yesterday
Gainers Nkarta, Inc. (NASDAQ: NKTX) shares climbed 140.9% to close at $18.72 on Monday after the company announced Phase 1 data from independent dose finding studies of its two... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Mid-Day Market Update: Crude Oil Tumbles Over 6%; Nkarta Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Dow Jones dropping more than 400 points on Monday. 
Via Benzinga
34 Stocks Moving In Monday's Mid-Day Session
Gainers Nkarta, Inc. (NASDAQ: NKTX) shares jumped 108.6% to $16.21 after the company announced Phase 1 data from independent dose finding studies of its two lead chimeric antigen... 
Via Benzinga
Why Is Nkarta (NKTX) Stock Soaring 90% Today?
Nkarta (NKTX) stock is rocketing higher on Monday after the company released preliminary data from a Phase 1 clinical trial. 
Via InvestorPlace
Mid-Morning Market Update: Markets Open Lower; Dow Tumbles Over 300 Points
U.S. stocks opened lower this morning, with the Dow Jones dropping more than 300 points on Monday. 
Via Benzinga
Benzinga's Daily Brief On Trending Tickers For April 25, 2022: Twitter, Coca-Cola, Nkarta, And More
Benzinga’s “Daily Brief On Trending Tickers” features top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items... 
Via Benzinga
How Nkarta Stock Scored A 90% Surge On Its 'Natural Killers' In Cancer
The biotech reported promising results for cell therapies without extreme side effects. 
Via Investor's Business Daily
Why Nkarta Stock Is Soaring Today
Nkarta Inc (NASDAQ: NKTX) shares are trading higher Monday morning after the company announced positive preliminary Phase 1 data from independent dose finding studies. The... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new... 
Via Benzinga
43 Stocks Moving In Tuesday's Mid-Day Session
Gainers Forge Global Holdings Inc. (NYSE: FRGE) shares jumped 67.7% to $16.95. True Global Ventures’ portfolio company Forge Global Holdings completed its business... 
Via Benzinga
35 Biggest Movers From Friday
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) shares surged 96% to close at $38.41 on Friday. The FDA approved ChemoCentryx’s Tavneos (avacopan) as an adjunctive treatment for... 
Via Benzinga
61 Biggest Movers From Yesterday
Gainers Arbutus Biopharma Corporation (NASDAQ: ABUS) shares jumped 44.1% to close $4.61 on above-average volume on Wednesday. The Patent Trial and Appeals Board has turned down... 
Via Benzinga
Topics Intellectual Property
28 Stocks Moving In Friday's Mid-Day Session
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) shares climbed 60.8% to $31.51. The FDA approved ChemoCentryx’s Tavneos (avacopan) as an adjunctive treatment for anti-neutrophil... 
Via Benzinga
Nkarta Expects Initial Data From CAR NK Cell Therapy In Blood Cancer In 2022
Nkarta Inc (NASDAQ: NKTX) has updated guidance on initial data readout of Phase 1 trial of NKX101 in relapsed or refractory acute myeloid leukemia or higher-risk... 
Via Benzinga
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today